Small molecule · developed by Insmed
Liposomal amikacin is an inhaled aminoglycoside antibacterial delivered as a liposomal dispersion via nebulization.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 4, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01315678 | Phase 3 | Pseudomonas Aeruginosa Infection | Completed | INSM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pseudomonas Aeruginosa Infection
Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.
See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INSM catalysts and pipeline →